Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Offices

NEW HAVEN, USA
5 SCIENCE PARK
395 WINCHESTER AVENUE
NEW HAVEN, CT, 06511
USA

People

CEO
Founder
Board of Directors
Boards

Funding

TOTAL $15M
FUNDING TOTAL $15M
Series A, 9/2013
Canaan Partners
5AM Ventures
Connecticut Innovations
Elm Street Ventures
$15M

Tags

Arvinas

Arvinas is a pharmaceutical company focused on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Central to Arvinas’ proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body. This strategy of degradation versus protein inhibition holds several advantages including the potential to target proteins that are not currently ‘druggable’ using a small molecule approach.

Recent Milestones

Videos

Screenshots

Arvinas screenshot
Above: Homepage
Uploaded: 9/27/13

Sources

  1. Arvinas Raises $15M Series A for Protein-Degrading Therapies (pevc.dowjones.com) [edit]
Edit This Page
Last Edited 1/26/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy